Improving Outcomes in OAB: New and Emerging Strategies to Reduce Symptom Burden and Treatment Adverse Effects (Archived CME/CE Monograph)

This educational activity has expired. You will not be able to claim credit for this activity.

Activity Description and Purpose

Overactive bladder is a common problem among men and women, with bothersome symptoms that can have significant negative physical, social, and emotional consequences. Treatment plans, which should be individualized according to patient needs and assessment of a treatment’s benefits and risks, often include pharmacologic therapy with an antimuscarinic and/or a β3-adrenoceptor agonist. Poor treatment adherence/persistence, however, limits success and patient satisfaction. This activity will review efficacy, safety, and tolerability data for overactive bladder pharmacologic therapies, including a new β3-adrenoceptor agonist, and their relevance for counseling to improve treatment adherence. The activity will also focus on the effect of pharmacologic therapies on cognitive function, which is of particular concern because older individuals are highly represented in the population with overactive bladder. Finally, case-based discussions will provide insights from experts for practical approaches to optimize patient care. The desired results of this activity are for clinicians to improve their diagnosis and treatment of overactive bladder.

Target Audience

This educational activity is intended for urologists, urogynecologists, physician assistants, nurse practitioners, nurses, and other clinicians caring for patients with overactive bladder.

Learning Objectives

After completing this activity, participants will be better able to:

  • Apply efficacy and tolerability clinical data to develop long-term treatment plans for patients with overactive bladder
  • Incorporate medication reviews into patient encounters
  • Compare the data on central nervous system effects of antimuscarinic overactive bladder medications with those of β3-adrenoceptor agonists
  • Describe the pharmacologic, efficacy, safety, and tolerability profiles of new and emerging treatments for overactive bladder
Course summary
Course opens: 
04/01/2021
Course expires: 
04/30/2025

Faculty

Roger Dmochowski, MD, MMHC, FACS (Chair)
Associate Surgeon in Chief
Professor of Surgery
Professor of Urology
Professor of Obstetrics and Gynecology
Vice Chair, Section of Surgical Sciences
Vanderbilt University Medical Center
Nashville, Tennessee

Benjamin M. Brucker, MD
Associate Professor
Departments of Urology and Obstetrics and Gynecology
Director, Female Pelvic Medicine & Reconstructive Surgery and Neurourology
New York University Langone Health
New York, New York

Kathleen C. Kobashi, MD, FACS
Head, Section of Urology and Renal Transplantation
Virginia Mason Medical Center
Seattle, Washington

Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.

Disclosures

Faculty

Benjamin M. Brucker, MD, is a consultant for Allergan, Click Therapeutics, Inc, and Urovant Sciences, Inc; is on the speakers bureau for Allergan; is a contracted researcher for Boston Scientific Corporation; and has ownership interest (future stock options) in Watkins-Conti Products, Inc.

Roger Dmochowski, MD, MMHC, is a consultant for BlueWind Medical, Caldera Medical, and Viveve; and a medical monitor for BlueWind Medical, Caldera Medical, and Viveve.

Kathleen C. Kobashi, MD, is a consultant for Allergan, Contura Ltd, and Medtronic; is on the speakers bureau for Allergan and Medtronic; and is a contracted researcher for Allergan.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners and Managers

MedEdicus planners and managers have no relevant commercial relationships to disclose.
 

For Physicians:

ACCME Accreditation Statement

image MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses:

Interprofessional Joint Accreditation Statement

image In support of improving patient care, Amedco LLC is jointly accredited by the ACCME, the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Credit

Amedco LLC designates this activity for a maximum of 1.5 ANCC contact hours.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Urovant Sciences, Inc.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs or devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Urovant Sciences, Inc, or Urology Times.

©2021 MedEdicus LLC. 230.3

Please login or register to take this course.

Clicking Register indicates that you have reviewed the CME/CE information for this activity.